Adagrasib gets accelerated approval for KRAS G12C-mutated NSCLC

Share This Post

Jan 2023: Adagrasib (Krazati, Mirati Therapeutics, Inc.), a RAS GTPase family inhibitor, was given accelerated approval by the Food and Drug Administration (FDA) for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as identified by an FDA-approved test, who have received at least one prior systemic therapy.

As additional companion diagnostics for Krazati, the FDA additionally approved the QIAGEN therascreen KRAS RGQ PCR kit (tissue) and the Agilent Resolution ctDx FIRST Assay (plasma). The tumour tissue should be examined if there was no indication of a mutation in the plasma sample.

The KRYSTAL-1 clinical trial (NCT03785249), which involved patients with locally advanced or metastatic NSCLC with KRAS G12C mutations, served as the foundation for the approval. Efficacy was assessed in 112 individuals whose illness had advanced during or after receiving immune checkpoint inhibitors and platinum-based chemotherapy, either concurrently or sequentially. Patients got adagrasib 600 mg twice daily until their condition progressed or the side effects became intolerable.

The primary efficacy outcome measures were duration of response and confirmed objective response rate (ORR) in accordance with RECIST 1.1, as assessed by a blinded independent central review (DOR). The median DOR was 8.5 months (95% CI: 6.2, 13.8), and the ORR was 43% (95% CI: 34%, 53%).

Diarrhea, nausea, fatigue, vomiting, musculoskeletal pain, hepatotoxicity, renal impairment, dyspnea, edoema, decreased appetite, cough, pneumonia, disorientation, constipation, abdominal pain, and QTc interval prolongation were the most frequent side effects ( 20%). Reduced lymphocytes, increased aspartate aminotransferase, increased sodium, decreased sodium, decreased haemoglobin, increased creatinine, decreased albumin, increased alanine aminotransferase, increased lipase, decreased platelets, decreased magnesium, and decreased potassium were the most prevalent laboratory abnormalities ( 25%).

Adagrasib tablets should be taken orally twice day at a dose of 600 mg until the condition progresses or there is intolerable toxicity.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

After amazing growth of CAR T-Cell therapy what's next
CAR T-Cell therapy

After amazing growth of CAR T-Cell therapy: what’s next?

CAR T-cell therapy has rapidly transformed cancer treatment by reprogramming a patient’s T-cells to attack cancer cells, demonstrating remarkable success in hematologic cancers. Advances in genetic engineering, regulatory support, and investment are driving further expansion. Researchers are now tackling the challenges of applying this therapy to solid tumors, aiming to enhance efficacy and accessibility, marking a new era in personalized cancer therapy and immunotherapy.

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy